Create a free research account to view current pricing and place an order.
How does KPV work in research models?
KPV is a tripeptide derived from alpha-MSH research. It is associated with melanocortin-linked anti-inflammatory signaling, NF-kB modulation, and mucosal/skin inflammation pathway support.
What is the half-life of KPV?
Half-life: Short acting.
Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise.
Research dosing reference
250-1000 mcg one to two times daily depending on inflammation target.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 250 mcg | 5 units |
| 500 mcg | 10 units |
| 1000 mcg | 20 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
How is KPV reconstituted?
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
Injection timing
Daily or split AM/PM depending on protocol objective. Local versus systemic placement should be determined by research design and clinician preference.
Beginner escalation
Start with conservative exposure to evaluate injection-site tolerance and systemic response before increasing or layering additional repair agents.
Side-effect mitigation
Monitor injection tolerance, GI response, fatigue, headache, or unexpected immune/inflammatory changes.
Stack compatibility
Pairs with BPC/TB/GHK-Cu when inflammation is part of the repair target; avoid over-stacking anti-inflammatory agents initially.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Short-course, tightly controlled protocols are preferred. Reassess immune/inflammatory response before repeating or extending, especially with irritating or immune-active peptides.
Frequently asked questions
What is KPV and how is it studied?
KPV is a tripeptide derived from alpha-MSH research. It is associated with melanocortin-linked anti-inflammatory signaling, NF-kB modulation, and mucosal/skin inflammation pathway support. KPV is catalogued in the Recovery / Regenerative group of this reference and is studied in laboratory and in-vitro models only.
What is known about the half-life of KPV?
Reference half-life for KPV: short acting. Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise. Published pharmacokinetic figures come from research and clinical-literature contexts and are listed here as reference values for laboratory work only, not as guidance for any person or animal.
How is KPV stored?
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically. Lyophilized research peptides are generally kept cold, dry, and away from light, and reconstituted solutions are labeled with concentration and date. Follow the storage conditions documented for the specific lot you receive.
How is KPV reconstituted for laboratory work?
The reference reconstitution for the 10 mg vial is 2 mL BAC Water, which gives a concentration of about 5 mg/mL. Concentration equals peptide mass divided by diluent volume, so adding more liquid lowers the concentration. Add diluent slowly down the vial wall, swirl rather than shake, and confirm the arithmetic before preparing any research solution.
Is KPV FDA approved?
No. The research-grade KPV described here is an investigational, research-use-only material and is not an FDA-approved drug product. Where an approved pharmaceutical form of a compound exists, it is a separate prescription product. This reference is not medical advice, and the material is not for human or animal consumption.
KPV product overview · KPV cost · All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration